公开(公告)号：US20190216975A1

公开(公告)日：2019-07-18

申请号：US16250349

申请日：2019-01-17

申请人： GENE'E TECH CO., LTD.

发明人： CHUNG-HAO WANG ,  SHU-JYUAN YANG ,  LI-CHENG PAN

IPC分类号： A61L26/00 ,  A61K38/17 ,  A61K31/728 ,  A61K31/65 ,  A61K31/635 ,  A61K31/4439 ,  A61K31/137 ,  A61K39/395

CPC分类号： A61L26/0052 ,  A61K31/137 ,  A61K31/4439 ,  A61K31/635 ,  A61K31/65 ,  A61K31/728 ,  A61K38/1709 ,  A61K38/178 ,  A61K39/3955 ,  A61L26/0023 ,  A61L26/0038 ,  A61L26/0066 ,  A61L26/008 ,  A61L2300/418 ,  A61L2300/45 ,  A61L2400/04 ,  A61L2430/34

摘要： A hemostatic material, a preparation method thereof, and a pharmaceutical composition containing the same are introduced. The hemostatic material includes 200 to 1600 parts by weight of water-insoluble gelatin and 100 to 1000 parts by weight of hydrating material. The preparation method for the hemostatic material includes the steps of (a) providing 200 to 1600 parts by weight of water-insoluble gelatin and 100 to 1000 parts by weight of hydrating material; and (b) combining the water-insoluble gelatin with the hydrating material to form a hemostatic material. The pharmaceutical composition includes an aforementioned hemostatic material and active pharmaceutical ingredients. Through the aforementioned hemostatic material, hemostatic products can increase the blood absorption capacity.

公开(公告)号：US20200114009A1

公开(公告)日：2020-04-16

申请号：US16258737

申请日：2019-01-28

申请人： GENE'E TECH CO., LTD.

发明人： CHUNG-HAO WANG ,  SHU-JYUAN YANG ,  CHIEN-MING LEE

IPC分类号： A61K47/36 ,  A61K47/69 ,  A61P31/04 ,  A61P1/04 ,  A61K47/34

摘要： A drug carrier, a drug structure, a purpose of the same, a method of making the same, and a method of using the same to inhibit H. pylori are revealed. The drug carrier includes a negatively charged polymer, chitosan and magnetic particles. The purpose of the drug carrier is to make a drug for inhibiting H. pylori. The drug structure includes a negatively charged polymer, chitosan, magnetic particles and an active ingredient. The method of making the drug structure includes mixing the negatively charged polymer solution, the chitosan solution, the magnetic particles and the active ingredient solution to form an initial solution and allowing ingredients in the initial solution to react and thereby form drug structure particles. The method of using the drug structure to inhibit H pylori includes administering the drug structure to an H. pylori colony. The drug carrier and drug structure demonstrate enhanced therapeutic efficacy.